STOCK COMMENTS / EPS CHANGES
Blackstone (BX) estimates, price target were increased at Jefferies. Estimates were raised through 2014. Outlook for growth and fee generation is the best it's been in years, said Jefferies. Buy rating and new $30 price target.
Eli Lilly (LLY) numbers were reduced at Guggenheim. Shares are now seen reaching $61. Estimates were also cut, as the company's breast cancer treatment failed in clinical trials. Outperform rating.
(MKC) estimates, price target were lowered at Jefferies. Shares are now seen reaching $76. Estimates were also cut, given the company's new guidance, Jefferies said. Buy rating.